Analysis of two different luteal phase support regimes and evaluation of in vitro fertilization-intra cytoplasmic sperm injection outcomes İki farklı luteal faz destek rejiminin analizi ve in vitro fertilizasyon-intrasitoplazmik sperm enjeksiyonu sonuçlarının değerlendirilmesi
Turkish Journal of Obstetrics and Gynecology, cilt.15, sa.4, ss.217-221, 2018 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 4
- Basım Tarihi: 2018
- Doi Numarası: 10.4274/tjod.73603
- Dergi Adı: Turkish Journal of Obstetrics and Gynecology
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.217-221
- Anahtar Kelimeler: Luteal phase support, gonadotropin-releasing hormone agonist, infertility, in vitro fenilizationn-intra cytoplasmic sperm injection
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To evaluate clinical pregnancy rates, miscarriage rates, ongoing pregnancy rates, and in vitro fertilization-intra cytoplasmic sperm injection outcomes of gonadotropin releasing hormone agonist (GnRHa) administration compared with human chorionic gonadotropin (hCG) application for luteal phase support. Materials and Methods: A total of 456 patients were included in the study. The patients were divided into two groups according to luteal phase support type: in group 1 (n=158), single-dose triptorelin acetate 0.1 mg was given on the sixth day after the oocyte pick-up (OPU). In group 2 (n=298), hCG 1500 IU was given on day 4, 7 and 10 after the OPU. Results: Both groups were homogeneous in relation with age and antral follicle count. The number of stimulation days and endometrial thickness on hCG day (mm) were found to be significantly higher in group 2 than in group 1 (p<0.001). The clinical pregnancy rate was slightly higher in the GnRHa group, but this difference was not statistically significant. Conclusion: Although there was no statistically significant difference between the two groups, luteal phase support with single-dose GnRHa might be as efficient as three doses of hCG. Large prospective, randomized-controlled studies are required comparing GnRHa and hCG for luteal phase support.